DOCSLIB.ORG

22Nd Annual Albert B. Sabin Medal Award Ceremony Roger I. Glass

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
22Nd Annual Albert B. Sabin Medal Award Ceremony Roger I. Glass nd Annual 22 Albert B. Sabin Gold Award Ceremony MedalPresented to Roger I. Glass, M.D., Ph.D. for his many contributions toward improving children’s health worldwide, including novel scientific research for the prevention of gastroenteritis from rotaviruses and noroviruses Tuesday, April 14, 2015 Bethesda North Marriott Hotel & Conference Center North Bethesda, MD Ceremony Program 5:30 PM REGISTRATION & REFRESHMENTS 6:30 PM WELCOME Peter J. Hotez, M.D., Ph.D. President, Sabin Vaccine Institute; Director, Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development; Dean, National School of Tropical Medicine at Baylor College of Medicine INTRODUCTION & PRESENTATION OF THE ALBERT B. SABIN GOLD MEDAL Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics, Emory University; Associate Director, Emory Vaccine Center Mathuram Santosham, M.D., M.P.H. Professor of Pediatrics and International Health Director, Center for American Indian Health Johns Hopkins University ACCEPTANCE Roger I. Glass, M.D., Ph.D. Director, Fogarty International Center Associate Director for International Research National Institutes of Health 7:30 PM RECEPTION About Sabin Vaccine Institute The Sabin Vaccine Institute (Sabin) is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs). Since its founding in 1993 in honor of Dr. Albert B. Sabin, the developer of the oral polio vaccine, Sabin has been at the forefront of global efforts to eliminate, prevent, and cure infectious and neglected tropical diseases. Sabin develops new vaccines, advocates for increased use of existing vaccines and promotes expanded access to affordable medical treatments in collaboration with governments, academic institutions, scientists, medical professionals and other non-profit organizations. About Dr. Albert B. Sabin After receiving his medical degree in 1931, Dr. Sabin began research on poliomyelitis (polio), which at the time had reached epidemic proportions around the globe. At the Children’s Hospital Research Foundation in Cincinnati, Ohio, he was able to prove that polio was an infection of the alimentary tract, indicating that polio might be prevented by an oral vaccine. Dr. Sabin’s early research was Dr. Sabin administers his oral vaccine to interrupted by World War two Cincinnati children - 1960s II. He joined the U.S. Army Epidemiological Board’s Virus Committee in 1941 and accepted assignments abroad, where he worked on vaccines for encephalitis, visceral leishmaniasis and dengue fever. At the end of World War II, Dr. Sabin returned to Cincinnati and resumed his research. He focused on isolating a mutant form of the polio virus incapable of producing the disease and thereby safe for introduction to the human body. The avirulent virus reproduced rapidly in the intestines, displacing lethal forms of the polio virus and providing protection from the disease. The oral vaccine was first tested outside the United States from 1957 to 1959 and introduced in the American public in 1959. Since then, Dr. Sabin’s vaccine has been used to eliminate polio in countries throughout the world. Dr. Sabin dedicated his entire professional career to the elimination of human suffering though his groundbreaking medical advances, while also waging a lifelong campaign against poverty and the resulting health inequities. It was in this spirit of commitment and dedication that his longtime friends and colleagues - led by Heloisa Sabin, his widow, and the late Dr. H.R. Shepherd, Sabin’s Founding Chairman - established the Sabin Vaccine Institute in 1993 following Dr. Sabin’s death. Dr. Sabin in his laboratory - 1955 Dr. Sabin - 1980s Images of Dr. Sabin courtesy of Winkler Center for the Health Professions, University of Cincinnati About Roger I. Glass, M.D., Ph.D Dr. Roger Glass, the Director of the Fogarty International Center at the National Institutes of Health, is internationally known for his lifelong contributions to understand and control rotavirus diarrhea through the use of vaccines. For more than three decades, he has pioneered research that has documented the epidemiology and enormous burden of rotavirus diarrhea throughout the world and worked to prevent this disease through the development and use of vaccines. These vaccines, including several that he has helped to develop, are now in use in the national immunization programs in more than 70 countries. They have already made a major impact to reduce both deaths and diarrheal hospitalizations, and improve the health of millions of children worldwide. As a young epidemiologist at the Centers for Disease Control and Prevention, Dr. Glass became engaged in research on enteric diseases and spent four years as a Scientist at the International Center for Diarrheal Disease Research in Bangladesh. This experience made him appreciate that diarrhea was one of the most important causes of death among children under 5 years and that rotavirus was the most common cause of both hospitalizations and deaths. After completing his Ph.D. on cholera with Prof. Jan Holmgren at the University of Gothenburg, Sweden, he joined the Laboratory of Infectious Diseases at NIH with Dr. Albert Kapikian to work on molecular and laboratory studies related to the first rotavirus vaccine. In 1986, he returned to CDC as Chief of the Viral Gastroenteritis Section where he spent two decades leading research on enteric infections. His group helped establish sentinel hospital surveillance of rotavirus, now ongoing in more than 60 countries around the world, which has resulted in data Dr. Glass with members of the Viral Gastroenteritis detailing the enormous Section, CDC - 2006 burden of this disease. This evidence established rotavirus as a global priority, and a prime target for vaccine development. His team also trained a cohort of epidemiologists and laboratory scientists who have become part of a global network monitoring the prevalence of disease, distribution of strains, and the impact of vaccines to improve child health. In 1995, he spent a year in the Global Program for Immunizations at WHO, where he developed a global strategy for surveillance of rotavirus hospitalizations that remains active to this day. Because of his concern that rotavirus vaccines produced by major manufacturers might be unaffordable for use in low-income countries, Dr. Glass worked in India for more than 20 years in partnership with Drs. M.K. Bhan, Harry Greenberg, and Krishna Ella and others to develop a novel vaccine that could be marketed to the public sector for $1.00 per dose, a fraction of the cost of the existing vaccines. This vaccine was just licensed in India and launched to the public by the Prime Minister of India, Narendra Modi. A similar effort has led to the development of a vaccine now licensed in Vietnam. Dr. Glass continues to work to improve the efficacy of live oral vaccines through research on a next generation of inactivated vaccines that would be administered by intramuscular or intradermal routes. Dr. Glass graduated from Harvard University, magna cum laude, in the History of Science and was awarded a Fulbright Fellowship to study at the University of Buenos Aires. He then received his M.D. from Harvard Medical School and Dr. Glass with Dr. M.K. Bhan at ROTAVAC® his M.P.H. from the Harvard School launch in Delhi - 2015 of Public Health. After clinical training in internal medicine at Mt. Sinai Hospital in New York City, and a year working at Oxford University and the Sysin Institute in Moscow, he joined the Epidemic Intelligence Service at CDC. Dr. Glass has received numerous awards, including the Charles C. Shepard Lifetime Scientific Achievement Award from CDC, the Dr. Charles Merieux Award from the National Foundation for Infectious Diseases, the Louis Pasteur Award from the Children’s Vaccine Initiative, and the Child Health Award from the Programme for Global Paediatric Research. He has served on the editorial board of Science and many other journals and on numerous advisory committees of the WHO, IOM and PAHO. He is a member of the Institute of Medicine of the U.S. National Academy of Sciences and delivered the 2014 John F. Enders Lecture at the Infectious Diseases Society of America’s annual meeting. He has co-authored more than 600 research papers and chapters and has lectured in five languages. He is married to Barbara J. Stoll, M.D., the George Brumley, Jr. Professor and Chair of the Department of Pediatrics at Emory University School of Medicine and Director of the Pediatric Center of Emory and Children’s Healthcare of Atlanta. He and his wife have three children. About the Albert B. Sabin Gold Medal Award Awarded annually since 1994, the Albert B. Sabin Gold Medal Award recognizes a researcher who has made extraordinary contributions in the field of vaccinology or a complementary field. This year marks the 22nd year that Sabin has bestowed the award. We applaud all of our past winners on their contributions to improving health worldwide. Albert B. Sabin Gold Medal Award Recipients (2015-1994) 2015 2014 2013 2012 Roger I. Mathuram Anne A. F. Marc Glass, Santosham, Gershon, LaForce, M.D., Ph.D. M.D., M.P.H. M.D. M.D. 2011 2011 2010 2009 Douglas R. John T. John D. Rino Lowy, M.D. Schiller, Clemens, Rappuoli, Ph.D. M.D. Ph.D. 2008 2007 2006 2005 Ruth S. Hilary William Albert Z. Nussenz- Koprowski, H. Foege, Kapikian, weig, M.D. M.D., M.D. M.D., Ph.D. (d. 2013) M.P.H. (d. 2014) 2004 2003 2002 2001 William S. Samuel L. Stanley A. John B. Jordan, Jr., Katz, M.D., Plotkin, Robbins, M.D. D.Sc. M.D. M.D. (d. 2008) 2000 1999 1998 1998 Ciro A. de Maj. Gen. Allen C. Myron M. Quadros, Philip K. Steere, Levine, M.D., M.P.H. Russell, M.D.
Load more

Recommended publications
  • TESTIMONY Peter J. Hotez MD, Phd President, Sabin Vaccine Institute
    TESTIMONY Peter J. Hotez MD, PhD President, Sabin Vaccine Institute “The Growing Threat of Cholera and Other Diseases in the Middle East” Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations Committee on Foreign Affairs United States House of Representatives March 2, 2016 Mr. Chairman and Members of the Subcommittee, thank you for the opportunity to speak with you today. I am Peter Hotez, a biomedical scientist and pediatrician. I am the dean of the National School of Tropical Medicine at Baylor College of Medicine and also the Texas Children’s Hospital Endowed Chair in Tropical Pediatrics based at the Texas Medical Center in Houston. I am also past president of the American Society of Tropical Medicine and Hygiene, and currently serve as President of the Sabin Vaccine Institute, a non-profit which develops vaccines for neglected tropical diseases (NTDs) through a product development partnership (PDP) model. This year I am also serving as US Science Envoy for the State Department and White House Office of Science and Technology Policy focusing on the urgency to develop vaccines for diseases that are emerging in the Middle East and North Africa due to the breakdowns in health systems in the ISIS occupied conflict zones in Syria, Iraq, Libya, and also Yemen. In my submitted written testimony I highlighted some of the successes in US global health policy, many of which can be attributed to the hard work of this Subcommittee working hand in glove with two presidential administrations since 2000. I cite evidence from the Global Burden of Disease Study (GBD) that brings together hundreds of scientists - I am also a part of this - who are measuring the impact of large scale global health programs.
    [Show full text]
  • Sabin in the News Recent Scientific Articles Sabin Vaccine Institute
    Home About Us News & Resources Support Sabin Sabin in the News October 2011 The Sabin Report | Volume 13 Issue 2 New York Times article featuring Dr. Peter Hotez's new study on increased Sabin Vaccine Institute Establishes a Houston prevalence of NTDs in Europe. Office Drs. Ciro de Quadros and In September 2011, the Zulfiqar Bhutta highlight Sabin Vaccine Institute the dire need for a dengue established offices in vaccine in an opinion Houston, Texas in the piece for GlobalPost. heart of the city's Texas Medical Center (TMC). The In an interview on Voice of new facilities will house the America Dr. Peter Hotez Sabin Vaccine Institute & focused on NTDs in Sub- Texas Children's Hospital Saharan Africa. Center for Vaccine Development, which will be An article by Dr. Neeraj operated in partnership Mistry was featured in a with Baylor College of special supplemental Medicine Department of section of the USA today, Pediatrics. Sabin Dr. Hotez and team at Sabin's new Houston facility titled "Neglected Diseases President, Dr. Peter J. in Developing Nations". Hotez will direct the new center. In an op-ed for the Houston Chronicle, Dr. The new space includes offices and laboratories through which the Peter Hotez writes about Sabin Vaccine Institute Product Development Partnership (PDP) will the establishment of the advance and strengthen its collaborative work in the field of vaccine new School of Tropical biotechnology. The change is the result of a year-long plan to expand Medicine at Baylor College the scope and depth of the Sabin PDP's partnership and to enhance of Medicine.
    [Show full text]
  • Peter Hotez, M.D., Ph.D. Biography
    Peter Hotez, MD, PhD, FASTMH, FAAP Peter J. Hotez, M.D., Ph.D., is professor of pediatrics and Molecular Virology and Microbiology at Baylor College of Medicine where he is also chief of a new Section of Pediatric Tropical Medicine and founding Dean of the National School of Tropical Medicine. In addition Prof. Hotez is the Texas Children's Hospital Endowed Chair of Tropical Pediatrics, and president of the Sabin Vaccine Institute. He will lead the new Sabin vaccine development program at Texas Children's Hospital and Baylor College of Medicine. He moves to BCM and Texas Children's from The George Washington University, where he has served as a Distinguished Research Professor and the Walter G. Ross Professor and Chair of the Department of Microbiology, Immunology and Tropical Medicine. Dr. Hotez is an internationally-recognized clinician and investigator in neglected tropical diseases and vaccine development. Diseases he studies include hookworm, schistosomiasis, Chagas disease, leishmaniasis, and malaria, among others, impacting hundreds of millions of children and adults worldwide. He obtained his undergraduate degree in molecular biophysics from Yale University in 1980, followed by a Ph.D. degree in biochemical parasitology from Rockefeller University in 1986 and a medical degree from Cornell University in 1987. He completed pediatric residency training at Massachusetts General Hospital from 1987 to 1989 and postdoctoral fellowship training in infectious diseases and molecular parasitology at Yale from 1989 to 1991. Dr. Hotez joined the Yale faculty as an assistant professor of pediatrics in 1992. He became an associate professor in 1995 before moving to the George Washington University as professor and chair in 2000.
    [Show full text]
  • Sabin Vaccine Report
    Volume VIII, Number 1 Sabin Vaccine Spring 2005 EPORT The newsletter of the Albert B. Sabin Vaccine InstituteR — dedicated to disease prevention www.sabin.org FDA Clears Human Hookworm Vaccine for Phase I Safety Trials Sabin/GW Researchers Receive Word on Investigational New Drug Status for Vaccine Clinical trials to test the safety of a gin safety trials is a major milestone for in individuals who suffer from hook- first-of-its-kind human hookworm vac- the human hookworm vaccine project,” worm infection.” cine will begin in the Washington, DC Hotez said. “It has taken an amazing Human hookworm infection is caused area in the coming weeks after the U.S. amount of our team’s effort to get us to by parasitic worms that fasten onto the Food and Drug Administration conferred the current stage of vaccine develop- inner layers of the small intestine using investigational new drug status on the ment. Of course, our ultimate goal is to their teeth-like projections and cause vaccine this past January. No current take this research to developing coun- blood loss at the attachment site. vaccine is available to prevent hook- tries where the vaccine will be tested Hookworm disease refers to the iron worm disease, which is one of the most Continued on page 4 common chronic infections of humans with an estimated 740 million cases in The village of Americaninhas, areas of rural poverty in the tropics in a rural part of Minas Gerais and subtropics. state in Brazil, is the focus of a The Human Hookworm Vaccine Ini- field study of hookworm dis- tiative (HHVI) is sponsored by the ease burden, being conducted Albert B.
    [Show full text]
  • 2015 Form 990 Or 990‐EZ
    ** PUBLIC DISCLOSURE COPY ** Return of Organization Exempt From Income Tax OMB No. 1545-0047 Form 990 Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations) 2015 Department of the Treasury | Do not enter social security numbers on this form as it may be made public. Open to Public Internal Revenue Service | Information about Form 990 and its instructions is at www.irs.gov/form990. Inspection A For the 2015 calendar year, or tax year beginning and ending B Check if C Name of organization D Employer identification number applicable: Address change Albert B. Sabin Vaccine Institute, Inc. Name change Doing business as 06-1389829 Initial return Number and street (or P.O. box if mail is not delivered to street address) Room/suite E Telephone number Final return/ 2000 Pennsylvania Avenue, NW 7100 202-842-8610 termin- ated City or town, state or province, country, and ZIP or foreign postal code G Gross receipts $ 17,938,597. Amended return Washington, DC 20006 H(a) Is this a group return Applica- tion F Name and address of principal officer:Amy Finan for subordinates? ~~ Yes X No pending same as C above H(b) Are all subordinates included? Yes No I Tax-exempt status: X 501(c)(3) 501(c) ( )§ (insert no.) 4947(a)(1) or 527 If "No," attach a list. (see instructions) J Website: | www.sabin.org H(c) Group exemption number | K Form of organization: X Corporation Trust Association Other | L Year of formation: 1994 M State of legal domicile: MD Part I Summary 1 Briefly describe the organization's mission or most significant activities: An organization of scientists, researchers, and advocates for a world free of needless suffering.
    [Show full text]
  • Bridging the Innovation Gap for Neglected Tropical Diseases in Mexico
    Bol Med Hosp Infant Mex 2011;68(2):138-146 article Bridging the innovation gap for neglected tropical diseases in Mexico: capacity building for the development of a new generation of antipoverty vaccines Maria Elena Bottazzi,1 Eric Dumonteil,2 Jesus G. Valenzuela,3 Miguel Betancourt-Cravioto,4 Roberto Tapia-Conyer,5 and Peter J. Hotez1,6 ABSTRACT The neglected tropical diseases (NTDs) represent a group of chronic parasitic and related infections that promote poverty because of their impact on child development, pregnancy, and worker productivity. The estimated 20 million Mexicans who live below the poverty line suf- fer disproportionately from a high prevalence of neglected tropical diseases such as amebiasis, Chagas disease, dengue, leishmaniasis, soil-transmitted helminth infections, trachoma, and vivax malaria. However, because the NTDs occur predominantly among the poor, new industrial and financial models are required to establish innovative technologies to address these conditions in Mexico and elsewhere in Latin America. In response, the Slim Initiative for Antipoverty Vaccine Development was established to foster a public/private partnership between key academic, government, and industrial institutions in the U.S. and Mexico. Initial emphasis will be placed on developing new vaccines for Chagas disease and leishmaniasis, two of the highest burden NTDs in Mexico and Mesoamerica. Key words: public/private partnerships, vaccines, product development, technology transfer, vaccine manufacture. InTRODuCTIOn infectious diseases that
    [Show full text]
  • Social and Economic Impact Review on Neglected Tropical Diseases
    ECONOMIC POLICY / BRIEFING PAPER in conjunction with Social and Economic Impact Review on Neglected Tropical Diseases Jeremiah Norris Carol Adelman Yulya Spantchak Kacie Marano November 2012 Hudson Institute’s Center for Science in Public Policy in conjunction with The Global Network for Neglected Tropical Diseases an initiative of the Sabin Vaccine Institute Social and Economic Impact Review on Neglected Tropical Diseases November 2012 Contributors Jeremiah Norris Carol Adelman Senior Fellow and Director Senior Fellow and Director Center for Science in Public Policy Center for Global Prosperity Yulya Spantchak Kacie Marano Research Fellow and Deputy Director Project Manager and Research Associate Center for Science in Public Policy Center for Science in Public Policy Table of Contents I. Executive Summary……………………………………………………………………...i II. Introduction…………………………………………………………………………….1 III. Background……….…………………………………………………………………...2 IV. The Macroeconomic Impact of NTDs………………………………………………...4 V. Integration…………………………………………………………………………….16 VI. Key NTD Policy Issues……………………………………………………………...19 VII. The Role of the Corporate Sector in NTDs…………………………………………21 VIII. Conclusions and Recommendations……………………………………………….22 Appendix A………………………………………………………………………………25 I. Executive Summary The Hudson Institute’s Center for Science in Public Policy entered into a partnership with the Sabin Vaccine Institute’s Global Network for Neglected Tropical Diseases (GNNTD) to undertake a comprehensive research and policy analysis study on the economic impact of neglected
    [Show full text]
  • Vaccinology in Latin America © 2018 Sabin Vaccine Institute
    Vaccinology in Latin America © 2018 Sabin Vaccine Institute. All rights reserved. The material in this document may be freely used for educational or noncommercial purposes, provided that the material is accompanied by an acknowledgement. The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine. Recommended citation: Andrus et al. Vaccinology in Latin America: A Resource for Immunization Managers. Washington, D.C.: Sabin Vaccine Institute; 2018. Design: Renée Saunders Translation: Silvia Colla Contents Preface ........................................................................................................................................................................................................................1 MODULE 1: EXISTING VACCINES AND VACCINES IN DEVELOPMENT ..................................................................................
    [Show full text]
  • Sabin Vaccine Report
    Volume IV, Number 1 Sabin Vaccine June 2001 EPORT The newsletter of the Albert B. Sabin Institute —dedicatedR to disease prevention www.sabin.org Walker’s Cay Colloquium Catalyzes Work on Cancer Vaccines and Immunotherapy 3rd Annual Sabin Institute-Sponsored Meeting Convened in March at Walker’s Cay, Abaco, Bahamas Thirty of the world’s leading cancer of the colloquium, said the meeting “was notherapy to learn from each other and vaccine scientists spent three days in a great success since it provided an ex- to discuss issues that are critical for the intense, unusually open discussions of cellent opportunity for top scientists in improvement of cancer treatments.” Jef- their newest research data and ideas at the field of tumor vaccines and immu- frey Schlom, head of the Laboratory of the Sabin Vaccine Institute’s Tumor Immunology and Biology Third Annual Walker’s Cay Col- at the National Cancer Institute loquium on Cancer Vaccines in also served as co-chair. The March. Their goal was to accel- Walker’s Cay Colloquium follows erate progress toward develop- a peer review format; emphasiz- ment of vaccines to treat and pre- ing an unusually open discussion vent various forms of cancer. of ideas and data so new they have Most of the renowned scientists not yet been published. It is reported learning new informa- multidisciplinary, involving ex- tion that will speed their own re- perts in oncology, immunology, search. Several said they formed microbiology, biochemistry, he- new, multi-institution collabora- matology and several other fields. tions at the meeting. It differs from most scientific Ralph A.
    [Show full text]
  • SABIN VACCINE REPORT the Newsletter of the Albert B
    SABIN VACCINE REPORT the newsletter of the Albert B. Sabin Vaccine Institute at Georgetown University Volume I, Number 1, September 1998 IN THIS ISSUE Institute Announces Sabin Vaccine Institute Announces Sabin-Hilleman Fellows Program Sabin and Hilleman are the inspiration for program aimed at promoting Sabin-Hilleman Fellows Program vaccinology and immunology. BY ERICA SEIGUER By participating in existing internships, or in projects 1 In keeping with one of its central missions, the Albert designed through a collaboration between the stu- B. Sabin Vaccine Institute has recently created the Sabin- dent and mentor, the Sabin-Hilleman Fellows will Neal Nathanson: New OAR Head Brings Diplomacy, Toughness Hilleman Fellows Program. A tribute to the pioneering work be exposed to the latest in vaccine design and imple- Renowned for his work on polio of two great figures in vaccinology, Albert B. Sabin and Maurice mentation. Possible projects might include intern- epidemiology, Nathanson filled the vacancy left by Bill Paul in November 1997. R. Hilleman, the Fellows Program will nurture talented high ships at the Global Programme for Vaccines and Im- 1 school students and undergraduates as they pursue their in- munization at the World Health Organization or in Op/Ed terests in the health sciences, particularly in vaccinology and a research laboratory at the National Institutes of Vaccines as an Instrument of immunology. Sabin Vaccine Institute Chairman H.R. Shep- Health. International Diplomacy 2 herd, a close friend of both Hilleman and the late Sabin, un- The Institute will begin the selection pro- derscores that the program is designed to encourage the next cess in February 1999, when application materials A Model of Government-Industry Collaboration, Avirons Intranasal generation of scientists and health professionals to dedicate are due.
    [Show full text]
  • SABIN VACCINE REPORT the Newsletter of the Albert B
    SABIN VACCINE REPORT the newsletter of the Albert B. Sabin Vaccine Institute at Georgetown University Volume II, Number 1, March 1999 IN THIS ISSUE Gates donates $100 million for childrens vaccines Rotavirus vaccine developed The newly developed vaccine for BY JOHN CLYMER AND DIANE MYERS Decreasing the lag time intestinal disease could improve the health of over 500 million children Microsoft billionaires Bill and Melinda Gates have Why is the Gates Foundation program of such importance? made a $100 million gift to establish a program to acceler- New, life-saving vaccines generally are in broad use in in- worldwide. ate access to new vaccines for children in developing na- dustrialized countries several years before they become widely 1 tions. The goal of the Bill and Melinda Gates Children’s used in developing countries where the need is greatest. This Vaccine Program’s is to significantly reduce the time it cur- time lag in vaccine “uptake” is due to economic, logistical rently takes for vaccines to reach children living in poor coun- and other challenges. tries. “We have a social imperative to work together to The initiative is a program of the William H. Gates SPECIAL REPORT: MALARIA address this basic inequity,” said Bill Gates, trustee of the A report on the impact of malaria on Foundation and will Fiset photo by PATH/J. William H. Gates Foundation. global health, the search for a vaccine, be administered by Sabin Vaccine Institute chairman and the risks travelers face when the Program for H. R. “Shep” Shepherd ap- visiting malaria-endemic areas. Appropriate plauded Gates’ vision and the es- 2-5 Technology in tablishment of the Children’s Vac- Health (PATH).
    [Show full text]
  • Schistosomiasis Vaccine Initiative Gaining Momentum
    February 2009 Volume 11, issue 1 NEW LOOK FOR SVI Dear Friends of the Sabin Vaccine Institute, We're pleased to share with you our latest newsletter. And, starting March 1st, Sabin will have a new address. You can find us at: 2000 Pennsylvania Avenue NW, Suite 7100 Washington DC 20006 Our telephone numbers will remain the same. The Sabin Vaccine Institute is proud to unveil its new logo, We want to take this opportunity to thank you for your support and along with a revamped interest in the many programs of the Sabin Vaccine Institute. website. The web address is the same--please take a look at www.sabin.org. Global Network Receives $34 Million Grant from the Bill & Melinda Gates SAVE THE DATE Foundation At the World Economic Summit in Davos, Switzerland, Bill Gates announced that the Global Network for Neglected Tropical Diseases, an initiative of the Sabin Vaccine Institute, has been awarded $34 million to help in the fight against Neglected Tropical Diseases. Click here to read more about the grant and about Global Network's "End the Neglect 2020" campaign. Pace Global Call To Action Draws Broad Please Save the Date Support The Sabin Vaccine Institute is pleased to announce our 16th annual Thanks to technological advances from the Gold Medal Award Ceremony vaccine industry and global funding on Tuesday April 28th, 2009 commitments from donors and foundations, at the countries can access pneumococcal vaccines Baltimore Marriott Waterfront more quickly and affordably than ever before. Baltimore, Maryland To impress upon governments the unprecedented opportunity to protect millions of children from this disease, Sabin's PACE program issued a Global Call to Action on Pneumococcal Disease REGISTER HERE FOR Prevention in Washington, D.C.
    [Show full text]